ARQ531: all 21 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingNCT07796373Phase 2
• A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)RecruitingNCT07734610Phase 1
• Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic LeukemiaNot yet recruitingNCT07690891Phase 2
• Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT07673367Phase 2
• Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 2
• Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT07557056Phase 2
• Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT07194980Phase 2
• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2
• Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaRecruitingNCT06572618Phase 2
• A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Phase 3
• A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingNCT05947851Phase 3
• Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
• A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)CompletedNCT05673460Phase 1Results posted
• A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)CompletedNCT06772818Phase 1
• A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)CompletedNCT06772805Phase 1
• A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)CompletedNCT06625827Phase 1
• A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)CompletedNCT06586671Phase 1
• A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)CompletedNCT06442436Phase 1
• A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingNCT05624554Phase 3
• A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)Active, not recruitingNCT05347225Phase 1
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2

← ARQ531 overview